Eli Lilly and Company has concluded the acquisition of biopharmaceutical company Morphic Holding at $57 per share, a strategic move aimed at bolstering its inflammatory bowel disease (IBD) portfolio.

Eli Lilly and Company announced the successful completion of its acquisition of Morphic Holding, Inc. Morphic is a biopharmaceutical company developing oral integrin therapies for treatment of serious ...

Eli Lilly is acquisitive, too, and just purchased a company called Morphic Holding ... Eli Lilly looks like a great stock to buy and hold for the long run, while its top-notch track record ...

The early trial of TERN-601 is encouraging, but I wouldn't buy shares of the stock just yet. It's still far too early in the ...

Eli Lilly(NYSE:LLY) is navigating a dynamic environment marked by both opportunities and challenges. Recent highlights ...

Discover Citi's bullish outlook on Eli Lilly with a $1,060 target. Is now the time to invest? Find key insights and price ...

Eli Lilly & Co (LLY – Research Report), the Healthcare sector company, was revisited by a Wall Street analyst today. Analyst Steve Scala from TD Cowen maintained a Buy rating on the stock and ...

Shares of Eli Lilly & Co. LLY sank 0.13% to $904.97 Wednesday, on what proved to be an all-around poor trading session for ...

The maintained Buy rating and price target signal confidence in Eli Lilly's continued growth and ... The company has also completed the acquisition of Morphic Holding (NASDAQ:MORF), Inc., adding ...

Barclays analyst Carter Gould maintained a Buy rating on Eli Lilly & Co (LLY – Research Report) today and set a price target of $1,025.00. The company’s shares closed last Friday at $922.12.